Evidence map›Paper›PMID 34717645›Full record

ArticleCancer cell international2021

Serum-derived exosomes promote CD8+ T cells to overexpress PD-1, affecting the prognosis of hypopharyngeal carcinoma.

Qian Gao, Hui-Ting Liu, Yu-Qin Xu, Lin Zhang, Yuan-Ru Liu, Qianqian Ren, Ju-Ping Sheng, Zhen-Xin Zhang

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Harnessing extracellular vesicle-mediated crosstalk between T cells and cancer cells for therapeutic applications.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  6. [Advances in salivary exosomal miRNAs in head and neck squamous carcinoma].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2024
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Qian Gao *Medical College of Nantong University, Nantong, China.
Hui-Ting Liu *Otorhinolaryngology Head and Neck Surgery Department, Affiliated Hospital of Nantong University, Nantong, China.
Yu-Qin XuOtorhinolaryngology Head and Neck Surgery Department, Affiliated Hospital of Nantong University, Nantong, China.
Lin ZhangOtorhinolaryngology Head and Neck Surgery Department, Haimen District People's Hospital, Nantong, China.
Yuan-Ru LiuOtorhinolaryngology Head and Neck Surgery Department, Affiliated Hospital of Nantong University, Nantong, China.
Qianqian RenOtorhinolaryngology Head and Neck Surgery Department, Affiliated Hospital of Nantong University, Nantong, China.
Ju-Ping ShengOtorhinolaryngology Head and Neck Surgery Department, Affiliated Hospital of Nantong University, Nantong, China. fyshjp@163.com.
Zhen-Xin ZhangOtorhinolaryngology Head and Neck Surgery Department, Affiliated Hospital of Nantong University, Nantong, China. zhangzhenxinent@ntu.edu.cn.ORCID http://orcid.org/0000-0002-3581-0818
Nantong University · CN

Funding

health research foundation for clinical oncology Y-XD2019-213people's livelihood scientific and technological innovation and demonstration promotion, nantong, jiangsu MS22021046
6 · The paper itself

Abstract

backgroundHypopharyngeal cancer (HPC) is associated with a poor prognosis and a high recurrence rate. Immune escape is one of the reasons for the poor prognosis of malignant tumors. Programmed cell death ligand 1 (PD-L1) and programmed cell death-1 (PD-1) have been shown to play important roles in immune escape. However, the role of PD-1/PD-L1 in HPC remains unclear. In this experiment, we investigated the effect of exosomes from HPC patient serum on CD8+ T cell function and PD-1/PD-L1 expression and, thus, on prognosis. We hope to provide guidance for the identification of new targets for HPC immunotherapy.

methodsPD-1 and CD8 expression in 71 HPC tissues and 16 paracarcinoma tissues was detected by immunohistochemistry. Concurrently, the clinicopathological data of the patients were obtained to conduct correlation analysis. Exosomes were isolated from serum and then identified by Western blotting (WB), transmission electron microscopy (TEM), and nanoparticle tracking analysis (NTA). Flow cytometry was used to assess the activity of CD8+ T cells after exosome stimulation. The effects of exosomes on the ability of CD8+ T cells to kill FaDu cells were assessed by CCK-8 assay. The expression of IL-10 and TGF-β1 was measured by enzyme-linked immunosorbent assay (ELISA). PD-L1 expression in HPC tissue samples was evaluated by immunohistochemistry, and the relationship between PD-1/PD-L1 expression and prognosis was investigated with patient specimens.

resultsPD-1 expression was significantly upregulated on CD8+ T cells in tumor tissues compared with those in normal tissues. The overall survival (OS) and disease-free survival (DFS) of PD-1-overexpressing patients were decreased. Serum exosomes from patients can elevate PD-1 expression on CD8+ T cells and suppress their killing capacity and secretory function. The rate of positive PD-L1 expression was increased in HPC tissues compared with paracancerous tissues. The DFS and OS of the PD-1(+)-PD-L1(+) group were significantly lower than those of the PD-1(-)-PD-L1(-) group.

conclusionOur findings indicate that serum exosomes from HPC patients can inhibit CD8+ T cell function and that the PD-1-PD-L1 pathway plays an important role in the immune escape of HPC. Exosomes combined with immunotherapy may guide the treatment of patients with advanced disease in the future.

Indexed as

ExosomesHNSCCImmunotherapyPD-1Prognosis

Identifiers

PMID34717645
PMCPMC8557583
OpenAlexW3210566010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.